Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers

Glutamate neurotransmission is a prioritized target for antipsychotic drug development. Two metabotropic glutamate receptor 2/3 (mGluR2/3) agonists (pomaglumetad [POMA] and TS-134) were assessed in two Phase Ib proof of mechanism studies of comparable designs and using identical clinical assessments...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropsychopharmacology (New York, N.Y.) N.Y.), 2020-10, Vol.45 (11), p.1842-1850
Hauptverfasser:	Kantrowitz, Joshua T, Grinband, Jack, Goff, Donald C, Lahti, Adrienne C, Marder, Stephen R, Kegeles, Lawrence S, Girgis, Ragy R, Sobeih, Tarek, Wall, Melanie M, Choo, Tse-Hwei, Green, Michael F, Yang, Yvonne S, Lee, Junghee, Horga, Guillermo, Krystal, John H, Potter, William Z, Javitt, Daniel C, Lieberman, Jeffrey A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antipsychotic Agents - therapeutic use Antipsychotics Clinical trials Cortex (cingulate) Double-Blind Method Drug development Glutamate receptors Glutamatergic transmission Glutamic acid receptors (metabotropic) Healthy Volunteers Humans Ketamine Ketamine - therapeutic use Mental disorders Neurotransmission Pharmaceutical Preparations Placebos Schizophrenia Schizophrenia - drug therapy Single-Blind Method
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!